Guideline Updates and Real-World Experiences in CLL: State-of-the-Art Evidence and Next Questions

Guideline Updates and Real-World Experiences in CLL: State-of-the-Art Evidence and Next Questions

Wednesday, June 30, 2021
Webinar -- 7:00 PM ET
http://www.clinicaloptions.com/ChicagoNCCNCLL2021Join2

Agenda

Welcome and Introduction (10 min)

Selecting Standard Therapy for Treatment-Naive CLL (20 min)

Selecting Standard Therapy for Previously Treated CLL (20 min)

Near Future Directions: Promising Agents and Combinations Under Investigation (20 min)

Panel Discussion and Audience Question and Answer Session (20 min)

Faculty

Program Director
William G. Wierda, MD, PhD

Professor
Department of Leukemia
Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Houston, Texas

Faculty
Jeremy S. Abramson, MD, MMSc

Associate Professor
Department of Medicine
Harvard Medical School
Director, Center for Lymphoma
Massachusetts General Hospital
Boston, Massachusetts

Faculty
Anthony Mato, MD

Associate Professor
Division of Leukemia
Memorial Sloan Kettering Cancer Center
New York, New York

Goal Statement
The goal of this activity is to improve the knowledge, confidence, and performance of learners to integrate recent findings into the treatment of patients with CLL/SLL.

Target Audience
This program is intended for physicians, physician assistants, nurses, pharmacists, and other healthcare professionals who care for patients with CLL/SLL.

Learning Objectives
At the conclusion of this activity, learners should be able to:

  • Design treatment plans for treatment-naive and relapsed/refractory CLL/SLL, including consideration of the agent’s toxicity profile, biomarkers, comorbidities, and patient preference
  • Appraise intraclass differences among agents with the similar therapeutic target in CLL/SLL, regarding selectivity, target binding, efficacy, and adverse event profiles
  • Evaluate the evolving role of measurable residual disease, allogeneic hematopoietic cell transplant, and CAR T-cell therapy
  • Develop strategies to address unique clinical challenges and leverage an understanding of the current data and NCCN Guideline to optimize outcomes for patients with CLL/SLL

Accreditation

Joint Accreditation Statement

In support of improving patient care, National Comprehensive Cancer Network (NCCN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physician Continuing Medical Education
NCCN designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education
NCCN designates this educational activity for a maximum of 1.5 contact hours.

Continuing Pharmacy Education

NCCN designates this application-based continuing education activity for 1.5 contact hour (0.15 CEUs) of continuing education credit. UAN: JA4008196-0000-21-036-L01-P.

Attention Pharmacists:
You must complete the post-test and evaluation within 30 days of the activity. Continuing pharmacy education credit is reported to the CPE Monitor once the post-test and evaluation are completed. Before completing these requirements, be sure your NCCN profile has been updated with your NABP e-profile ID and date of birth or your credit cannot be reported. If you have not already done so, please complete your e-profile at https://nabp.pharmacy/ to obtain your NABP e-Profile ID.

Physician Assistants
NCCN has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.5 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.

NCCN Continuing Education Disclosure Policy
It is the policy of NCCN that every 12 months, all faculty, moderators, activity planners and all internal planning staff participating in NCCN continuing education activities are expected to disclose any financial relationships with a commercial interest. In addition, all faculty presentations have been reviewed to ensure education is fair and balanced and that clinical content presented supports safe, effective patient care. Individuals who do not disclose relevant financial relationships will be disqualified from involvement in the CE activity as a content developer, planner, or presenter. Full disclosure of faculty relationships will be made prior to the activity.

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. NCCN and Clinical Care Options, LLC do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of NCCN and Clinical Care Options, LLC. Please refer to the official prescribing information for each product for discussion of approved indication, contraindications, and warnings.